Citi cuts target price for Novo Nordisk
Citi raised Novo Nordisk's 2026-2027 earnings forecasts by 2-3% but lowered later estimates due to margin pressures and higher research costs. The bank increased its Wegovy tablet peak sales forecast to $13bn from $10bn. Novo Nordisk shares closed at 249.90 DKK.
How this was made
The 30-second read
Why it matters
The downgrade signals potential near‑term weakness, but the raised short‑term earnings could support a rebound if execution improves.
Market read
Analyst target cuts are a primary catalyst for short‑term price moves in large‑cap pharma stocks.
What to watch
The $13 bn tablet Wegovy sales forecast may provide upside not fully reflected in the target price.
Background
Citi updated its valuation model for Novo Nordisk, raising near‑term earnings forecasts but lowering long‑term expectations due to margin pressure and research costs.
Ticker impact
Citi lowered Novo Nordisk's target price and trimmed long‑term forecasts, introducing new guidance for 2026‑2027.
likely downward pressure as investors price in the reduced target
Analyst target cuts historically trigger short‑term sell pressure, especially for a large pharma with high visibility.
Market effects
May dampen sentiment in the European pharma sector as peers are re‑rated.
Potential modest pullback in Copenhagen‑based health‑care stocks.
Limited to investors tracking major pharma earnings and guidance.
Counterpoint
Higher 2026‑2027 earnings forecasts could offset the target cut if tablet Wegovy gains market share.
Key entities
- companyNovo Nordisk
Danish pharmaceutical firm developing obesity drug Wegovy.
- analystCiti
Investment bank providing the target price revision.
